---
title: "Xtant Med | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 23.03 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295526518.md"
datetime: "2026-08-11T11:07:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295526518.md)
  - [en](https://longbridge.com/en/news/295526518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295526518.md)
generator: "portal-rs"
---

# Xtant Med | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 23.03 M

Revenue: As of FY2026 Q2, the actual value is USD 23.03 M, missing the estimate of USD 24.88 M.

EPS: As of FY2026 Q2, the actual value is USD -0.07.

EBIT: As of FY2026 Q2, the actual value is USD -8.798 M.

The provided Form 8-K from Xtant Medical Holdings, Inc. announces the company’s financial results for the second quarter of 2026 but does not include specific financial and operational metrics such as segment revenue, net income, gross margin, operating profit, operating costs, operating cash flow, free cash flow, or any unique company-specific indicators. Additionally, no outlook or guidance content is provided in this filing. 

#### Non-GAAP Adjusted EBITDA Definition

Xtant Medical Holdings, Inc. defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense; interest expense, net; and tax benefit (expense). This measure is further adjusted to add back or exclude non-cash compensation, unrealized foreign currency translation losses or gains, and other special items. These special items include write-off of distribution agreement deposit, divestiture/acquisition-related income and expenses, income related to transition services agreements, acquisition-related fair value adjustments, and separation-related expenses, as applicable. The company uses this non-GAAP measure for operating decisions, to understand investment allocation, for budgeting and spending decisions, and to facilitate comparisons of operational performance by factoring out charges not related to its regular, ongoing business.

### Related Stocks

- [XTNT.US](https://longbridge.com/en/quote/XTNT.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Xtant, Citing BioHorizons Partnership and High-Margin OsteoFactor Pro as Key Growth Drivers](https://longbridge.com/en/news/297358486.md)
- [Xtant Medical partners with BioHorizons for exclusive dental distribution of allogeneic growth factor tech in US, Canada](https://longbridge.com/en/news/297181832.md)
- [REG - Verition Fund Mgmt Spire Healthcare Grp - Form 8.3 - SPIRE HEALTHCARE GROUP PLC](https://longbridge.com/en/news/297798360.md)
- [If You Invested $1000 In Welltower Stock 20 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/297801413.md)
- [REG - Jefferies Intl Ltd Adv Medical Solutns. - Form 8.3 Advanced Medical Solutions Group Plc](https://longbridge.com/en/news/297631426.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**